secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001001233-26-000005
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path
--------------------------------------------------------------------------------

- FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.
- Positive mean annualized eGFR slope of 1.965 at Week 52 (95% CI -0.153, 4.083) across 32 patients; Week 104 slope 1.747.
- All 15 ERT-naïve patients achieved normal/supraphysiological α-Gal A activity up to 54 months; 18 ERT patients safely withdrew from ERT.
- 32 of 33 patients completed 52-week follow-up; ST-920 well-tolerated with no discontinuations due to AEs, no TMA or complement activation.
- Statistically significant improvements in SF-36 QoL and GSRS diarrhea scores at Week 52; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000100123326000005/0001001233-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000100123326000005/sgmo-20260203.htm
  HTML page:      https://secwatch.observer/filing/0001001233-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer